Regulatory – Page 5 – Alligator Bioscience

2023-08-21

Regulatory

Alligator Bioscience Receives European Medicine Agency Orphan Designation for Mitazalimab in Pancreatic Cancer

Lund, Sweden – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announces that the European Medicines Agency (EMA) has granted Orphan De ...

2023-07-13

Regulatory

Positive second interim analysis from OPTIMIZE-1 Phase 2 study shows increase in ORR* and favorable DoR** suggesting durable benefits of mit ...

2023-06-30

Regulatory

During June 2023, the number of shares and votes in Alligator Bioscience AB (“Alligator”) has increased as a result of the completion of the ...

2023-06-26

Regulatory

Continued follow-up on the futility analysis cohort (23 patients) showed deepening of tumor responses and an increase in Objective Response ...

2023-05-26

Regulatory

The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedis ...

2023-05-242023-05-24

Regulatory

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, ...

2023-05-18

Regulatory

Lund, Sweden – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announces that the U.S. Food and Drug Administration (FDA) has granted O ...

2023-05-122023-05-15

Regulatory

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, ...

2023-05-122023-05-12

Regulatory

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, ...